Diabetes Insipidus (DI) is a critical syndrome of fluid imbalance characterized by the production of large volumes of dilute urine (polyuria), leading to intense thirst (polydipsia). It stems from a problem with Arginine Vasopressin (AVP)—the Anti-Diuretic Hormone (ADH)—which regulates water reabsorption in the kidney.
Understanding the root cause is paramount, as DI treatment is fundamentally different from that of Diabetes Mellitus.
Defining the Problem: Polyuria and Dilution
The diagnosis of DI is based on two key laboratory findings:
- Polyuria: Urine output exceeding 50 mL/kg body weight per day (e.g., >3.5 Liters for a 70 kg adult).
- Inappropriate Dilution: Urine osmolarity is typically <300 mOsmol/L.
The Clinical Presentation
Patients with DI present with a classic triad of symptoms:
- Polyuria: Frequent urination, often including disruptive nocturia (waking up to urinate).
- Polydipsia: Excessive thirst due to the constant loss of water.
- Ice Water Preference: Many patients report a strong preference for cold or ice water to quench their intense thirst.
Pathophysiology: The Failure of Water Reabsorption
The antidiuretic effect of AVP is achieved by increasing the water permeability of the cells lining the distal tubule and medullary collecting ducts.
- In a healthy person, AVP is released, and these cells reabsorb water, concentrating the urine.
- In DI, these cells remain impermeable to water, leading to a large volume of dilute filtrate being excreted as urine.
Differentiating the Two Main Causes
The underlying cause dictates the treatment plan.
| Type of DI | Core Defect | Common Etiologies |
| 1. Central DI (CDI) / Pituitary DI | Decreased Secretion of AVP from the posterior pituitary. | Idiopathic (most common), Trauma (head injury), Iatrogenic (neurosurgery/radiation), Neoplastic, Infective (meningitis), Granulomatous (Sarcoidosis, TB). |
| 2. Nephrogenic DI (NDI) | Decreased Action (Resistance) to AVP at the collecting duct cells. | Drugs (most common): Lithium (for bipolar disorder) and Amphotericin B. Rarely, congenital causes. |
Diagnostic Investigations: The Fluid Deprivation Test
The gold standard for diagnosis and differentiation involves the controlled withdrawal of water, followed by an AVP challenge.
1. Initial Lab Work
- A 24-hour urine collection is essential to confirm the volume of polyuria.
- Measurement of urine osmolarity confirms inappropriate dilution (<300 mOsmol/L).
2. The Desmopressin Challenge (The Key Test)
After a fluid deprivation period fails to increase urine osmolarity, synthetic AVP (Desmopressin, 0.03 μg/kg S.C. or I.V.) is administered, and urine osmolarity is measured 2 hours later.
| Uosm Increase | Diagnosis | Implication |
| >50% | Severe Central DI (CDI) | The kidney can respond normally; the problem is lack of hormone supply. |
| <50% (Small or Absent) | Nephrogenic DI (NDI) | The kidney is resistant to the hormone’s action. |
Targeted Management: Treatment by Cause
1. Treatment for Central DI (CDI)
The goal is to replace the missing hormone.
- Desmopressin (DDAVP): This is a synthetic ADH analogue and a V2 receptor agonist. It effectively eliminates polyuria and polydipsia.
- Route and Dose: Intranasal administration is preferred (typical range 0.15–0.75 μg/kg daily), but S.C., I.V., and oral routes are also used.
2. Treatment for Nephrogenic DI (NDI)
Since the kidney is resistant to AVP, treatment aims to reduce the fluid load reaching the collecting duct.
- Thiazide Diuretics: These drugs, paradoxically, reduce polyuria in NDI. They induce mild volume depletion, which enhances the reabsorption of sodium and water in the proximal tubule, ultimately reducing the volume of filtrate that reaches the unresponsive collecting duct.
- NSAIDs (e.g., Indomethacin): These can be used adjunctively as they decrease renal blood flow and inhibit prostaglandin synthesis (prostaglandins normally inhibit ADH action).
For patients diagnosed with Central Diabetes Insipidus (CDI), the goal of treatment is to effectively replace the missing AVP using its synthetic analogue, Desmopressin (DDAVP). This drug is fundamental to therapy, offering a predictable reversal of DI symptoms.
Key Therapeutic Effects of Desmopressin
When Desmopressin is successfully administered to a patient with CDI, the following physiological changes are expected:
- Decreased Polyuria: Urine output dramatically falls as the kidney begins conserving water.
- Increased Urine Osmolarity: The urine becomes concentrated due to effective water reabsorption.
- Decreased Plasma Osmolarity: The plasma is diluted by the conserved water, correcting the hyperosmolar state of untreated DI.
- Slight Increase in Body Weight: The body retains the necessary water volume.
Pharmacological Advantages and Dosing
Desmopressin offers several advantages over native AVP for long-term clinical use:
| Feature | Detail | Clinical Significance |
| Potency | Approximately 12 times more potent than endogenous ADH as an antidiuretic. | Allows for effective results with a small dose. |
| Duration | Duration of action is around 8 hours. | Permits convenient dosing in three divided doses per day to maintain continuous control. |
| Route | Intranasal route is typically preferred for ease and patient adherence, despite its lower bioavailability (10–20%). | Offers flexibility for patient self-administration outside of a clinical setting. |
| Duration of Therapy | Treatment is generally life-long. | CDI is a chronic deficiency requiring permanent hormone replacement. |
Critical Safety Warning
The main side effect of CDI treatment (Desmopressin) is water intoxication, which manifests as hyponatremia. Physicians must caution patients against a fixed dosing regimen; patients should be instructed to take Desmopressin only when they feel excessive thirst to avoid replacing too much water and dangerously diluting their blood sodium.
References and Further Reading
- Christ-Crain, M., and Gaisl, O. “Diabetes insipidus.” La Presse Médicale, vol. 50, no. 4, 2021, 104093.DOI: 10.1016/j.lpm.2021.104093
- Garrahy, A., Moran, C., and Thompson, C. J. “Diagnosis and management of central diabetes insipidus in adults.” Clinical Endocrinology, vol. 90, no. 1, 2019, pp. 23–30.DOI: 10.1111/cen.13866
- Mutter, C. M., et al. “Diabetes Insipidus: Pathogenesis, Diagnosis, and Clinical Management.” Cureus, vol. 13, no. 2, 2021, e13523.DOI: 10.7759/cureus.13523
- Sands, J. M., and Bichet, D. G. “Nephrogenic diabetes insipidus.” Annals of Internal Medicine, vol. 144, no. 3, 2006, pp. 186–94.DOI: 10.7326/0003-4819-144-3-200602070-00007
- Society for Endocrinology Clinical Guidance. “Inpatient management of cranial diabetes insipidus.” Endocrine Connections, vol. 7, no. 7, 2018, G8-G11.URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC6013691/
- Mayo Clinic. “Diabetes insipidus – Diagnosis and treatment.” Mayo Clinic Patient Care and Health Information.URL: https://www.mayoclinic.org/diseases-conditions/diabetes-insipidus/diagnosis-treatment/drc-20351274
Dr. Kunal Varma Bheecarry, MD is a GMC registered substantive Consultant Physician in the UK, specializing in Internal Medicine. With more than 15 years of experience on the clinical frontlines in both General Internal Medicine and Acute Medicine, he is passionate about translating complex medical topics, common problems and clinical guidelines into clear, actionable knowledge for healthcare professionals and patients alike. Every article is written and rigorously reviewed by him and other registered medical professionals to ensure clinical accuracy, guideline compliance, evidence-based reliability, authoritativeness and trustworthiness.
Disclaimer: All content is purely educational and does not constitute personal medical advice. It is not a substitute for professional clinical advice and readers must consult their own primary team. All views and interpretations are mine and not related to the work place.